RCUS
Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology · US
$22.14
+0.09%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$22.44
From 52W high−29.87%
Volume3.52M
Market cap$2.82B
P/E (TTM)—
P/S (TTM)24.1x
Div yield—
Key dataOct 19, 2026
Open
$22.44
From 52W high
−29.87%
Volume
3.52M
Market cap
$2.82B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.3x
P/E (TTM)
—
RSI (14)
35.8
MomentumView details →
1D Return
+0.09%
YTD Return
−5.04%
SummaryUpdated Jun 1, 2026
Arcus Biosciences, Inc. (NASDAQ:RCUS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Hayward, California. The company went public in March 2018 and focuses on developing innovative cancer immunotherapies targeting the tumor microenvironment. Arcus has built a diverse pipeline of oncology treatments through both internal research and strategic partnerships with major pharmaceutical companies including Gilead Sciences, AstraZeneca, and Taiho Pharmaceutical. The company has advanced multiple drug candidates into late-stage clinical trials, with several programs expected to enter Phase 3 studies by 2025.
Similar companies
Latest newsMore news →
Arcus Biosciences, Inc. granted two new employees options to purchase a total of 9,150 shares of its common stock at an exercise price of $23.83 per share.10d agoArcus Biosciences granted stock options to purchase 21,200 shares at $26.39 per share to four new employees.25d agoArcus Biosciences announced it will host an investor event on October 20, 2026 in New York City to present new data from the ARC-20 platform study evaluating casdatifan as a treatment for kidney cancer across multiple lines of therapy.27d ago